The anti-calcitonin gene-related peptide (CGRP) monoclonal antibody erenumab (Aimovig) helps patients with chronic migraine convert to an episodic pattern soon after treatment initiation, new research suggests. In an open-label study, 71% of patients with chronic migraine treated for 1 year converted to episodic migraine. “Erenumab is related to a remarkably high percentage of pattern reversal